Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

Banner with ESDR, IEC, and IPC logos on the left, highlighting eczema research at the 55th Annual ESDR Meeting Heidelberg, Germany. A photo on the right shows Heidelberg with the Neckar River and historic stone bridge.

IEC-IPC Eczema and Psoriasis Research Incubator: Cross-Disciplinary Innovation Forum

55TH ANNUAL EUROPEAN SOCIETY FOR INVESTIGATIVE DERMATOLOGICAL RESEARCH MEETING (ESDR) | HEIDELBERG, GERMANY

September 9, 2026
 | 08:00–12:00 CEST
Location: Heidelberg Congress Center | Hall 2A, Level 1

Add this event to your calendar

Apple Google Outlook Outlook.com Office 365 Yahoo

The IEC–IPC Eczema and Psoriasis Research Incubator is a pre-congress, interactive forum designed to catalyze cross-disciplinary collaboration and accelerate innovation across inflammatory skin diseases. Featuring keynote presentations from global thought leaders, the program moves from cutting-edge insights into disease mechanisms and precision stratification to data-driven, translational approaches that inform real-world practice. Participants will engage in rapid-fire early-career presentations and structured small-group “Challenge Labs” focused on priority research themes, with the goal of identifying actionable gaps and shaping collaborative project concepts. This highly interactive format emphasizes practical outcomes, new partnerships, and sustained engagement beyond the session. Early-career investigators are strongly encouraged to apply.

Registration for the ESDR Congress is required to attend the IEC-IPC Program on Wednesday, September 9, 2026. 

Agenda

Registration and Breakfast

Welcome & Framing Remarks
Sara J. Brown, MD, PhD, FRCPE, FRSE, Scotland and Curdin Conrad, MD, Switzerland

KEYNOTE: From Mechanism to Precision: Defining Disease Endotypes
Johann Gudjonsson, MD, PhD, United States

KEYNOTE: From Data to Impact: Translating Evidence into Practice
Satveer Mahil, PhD, FRCP, United Kingdom

Lightning Talks: Early-Career Investigator Spotlights

  • Proteomic Signatures of Cardiovascular Risk Are Amplified in Psoriasis: A UK Biobank Proteomics Study – Ravi Ramessur, MD, PhD, United Kingdom
  • Atopic Dermatitis–Psoriasis Overlap: From Clinical Phenotypes to Therapeutic Strategies – Mengmeng Li, MD, PhD, China
  • Evolutionary Variation in the ERAP1-HLA Pathway and Psoriasis Susceptibility – Akiko Arakawa, MD, PhD, Germany
  • Untangling the Web: A Systems-Based Approach at Single-Cell Resolution Reveals Druggable Targets in Atopic Dermatitis – Tara Urselmann, MSc, Netherlands
  • Targeting Dysfunctional Endothelial Cells in Psoriasis – Matt Vesely, MD, PhD, United States

BREAK

Challenge Labs: Small Group Innovation Sessions

  • Shared Comorbidities – Facilitators: Anna López-Ferrer, MD, PhD, Spain and Caroline Mann, MD, Germany
  • Mechanisms of Disease – Facilitators: Claus Johansen, MSc, PhD, DMSc, Denmark and Danuta Gutowska-Owsiak, MD, PhD, DSc, Poland
  • Endotypes – Facilitators: Paola Di Meglio, PhD, United Kingdom and Mari Løset, MD, PhD, Norway
  • Treatment Stratification – Facilitators: Andreas Pinter, MD, PhD, Germany and Nick Reynolds, BSc, MBBS, MD, FRCP, United Kingdom
  • Precision Medicine – Facilitators: Nicole Ward, PhD, United States and John Common, PhD, United Kingdom
  • Paradoxical Cases – Facilitators: Johann Gudjonsson, MD, PhD, United States and Satveer Mahil, PhD, FRCP, United Kingdom
  • Global Challenges – Facilitator: Chris Griffiths, OBE, MD, FMedSci, United Kingdom

Small Group Reflections & Expert Commentary Panel

Closing Reflections & Next Steps

Program Chairs

Sara Brown, MD, PhD, FRCPE, FRSE

University of Edinburgh

Edinburgh, Scotland, United Kingdom

Bio

Johann Gudjonsson, MD, PhD

University of Michigan, Department of Dermatology

Ann Arbor, Michigan, United States

IPC Board Member

Bio

Fernando Valenzuela, MD

University of Chile, University of the Andes

Santiago, Chile

IPC Councilor

Bio

Nicole Ward, PhD

Vanderbilt University Medical Center and Vanderbilt University

Nashville, Tennessee, United States

IPC Councilor

Bio

Program Faculty

John Edmund Armourer Common, PhD

Newcastle University

Newcastle upon Tyne, United Kingdom

Bio

Curdin Conrad, MD

University Hospital of Lausanne

Lausanne, Switzerland

IPC Board Member

Bio

Paola Di Meglio, PhD

King’s College London

London, United Kingdom

IPC Councilor

Bio

Christopher Griffiths, OBE, MD, FMedSci

University of Manchester and King’s College London

London, United Kingdom

IPC Honorary Founder

Bio

Danuta Gutowska-Owsiak, MD, PhD, DSc

University of Gdańsk

Gdańsk, Poland

Bio

Claus Johansen, MSc, PhD, DMSc

Aarhus University Hospital

Aarhus, Denmark

IPC Councilor

Bio

Anna López Ferrer, MD, PhD

Hospital de la Santa Creu i Sant Pau

Barcelona, Spain

IPC Councilor

Bio

Mari Løset, MD, PhD

Norwegian University of Science and Technology and St. Olavs Hospital, Trondheim University Hospital

Trondheim, Norway

IPC Councilor

Bio

Caroline Mann, MD

University Medical Center of the Johannes Gutenberg University

Mainz, Germany

Bio

Satveer Mahil, PhD, FRCP

St John’s Institute of Dermatology

London, United Kingdom

IPC Councilor

Bio

Andreas Pinter, MD, PhD

University Hospital Frankfurt

Frankfurt, Germany

IPC Councilor

Bio

Nick Reynolds, BSc, MBBS, MD, FRCP

Newcastle University

Newcastle upon Tyne, United Kingdom

IPC Councilor

Bio

This program is supported in part by

A line drawing of a lion walking above the word LEO with a horizontal line underneath, and LEO FOUNDATION written in large capital letters below, symbolizing strength and dedication to advancing eczema research.

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026